Sanofi Pasteur Head Loew On The Vaccine Unit's Future Growth Drivers

David Loew talked to Scrip about the next-generation meningococcal vaccine candidate MenQuadfi and a monoclonal antibody that may be the first RSV treatment for infants.

Healthcare Industry and Vaccine Research. Conceptual Illustration. - Illustration
Sanofi Pasteur's pipeline includes next-generation meningococcal vaccine and monoclonal antibody and vaccine for RSV

More from R&D

More from Scrip